Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
BioMarin Pharmaceutical Inc (0HNC) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of BioMarin Pharmaceutical Inc $64.66, price $57.76, upside +12.0%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
BP
Broad data
Sep 24, 2026
BioMarin Pharmaceutical Inc
0HNC · LSEUndervaluedQuality growthThe stock appears undervalued with acceptable quality.
✓Fair value $64.66 · Undervalued (+12.0%)
✓Quality 67/100
!Mixed Growth (revenue 5y +11.8 %/yr)
!Thin margins · 8.3% net margin (TTM)
✓generates free cash flow
!Narrow moat 43/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
10‑month range $49.39 – $70.49 · fair‑value band $57.54 – $74.98 · the $57.76 price screens below the $64.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.
Company profile
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Show more
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Stock analysis
BioMarin Pharmaceutical Inc (0HNC) currently trades at $57.76, while our model-based Fair Value estimate is $64.66, implying the stock looks roughly 10.7% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $78.85 per share, and 8 of the 24 models we run sit above the $57.76 price.
Bear case: the Economic Profit group reads lowest at $20.54, and 16 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $57.54 (bear) to $74.98 (bull), the price of $57.76 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality).
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BioMarin Pharmaceutical Inc reported revenue of $3.2B in FY2025 versus $1.8B in FY2021, a compound +14.9%/yr. Reported net income was $26.8M in FY2025.
Key figures
Market cap $11.1B · P/E ratio 2.7 · P/S ratio 0.02 · EPS (TTM) $0.2150 · Net margin 0.8% · Return on equity 4.5% · Return on assets (EBIT) 3.2% · Operating margin 18.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
Fair Value models
Bear $57.54
Fair Value $64.66
Bull $74.98
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1626 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings
$8.32
$9.49
$11.84
75
FCF DCF
$70.08
$108.19
$218.37
74
Growth DCF
$66.79
$117.92
$213.93
72
All 24 models by family
DCF Models
FCF DCF
$70.08
$108.19
$218.37
74
Owner Earnings
$8.32
$9.49
$11.84
75
5Y Revenue Exit
$45.90
$73.01
$125.74
68
5Y EBITDA Exit
$48.94
$79.51
$135.49
70
5Y P/E Exit
$27.07
$34.91
$43.07
69
10Y Revenue Exit
$51.94
$90.21
$128.39
64
10Y EBITDA Exit
$55.14
$95.99
$168.32
63
10Y P/E Exit
$39.98
$54.50
$74.70
62
Earnings-Based
Graham-Dodd
$1.02
$7.13
$10.01
63
Lynch FV
$2.22
$3.17
$4.12
61
PEG = 1.0
$2.22
$3.17
$4.12
57
EPV
$27.78
$31.01
$33.79
70
Multiples
P/E Multiple
$2.26
$3.01
$3.76
63
P/S Multiple
$1.92
$2.56
$3.20
58
P/B Multiple
$1.92
$2.56
$3.20
55
EV/EBIT
$47.81
$61.29
$74.78
63
EV/EBITDA
$40.93
$52.12
$63.31
64
EV/Revenue
$34.63
$46.31
$58.00
52
Asset-Based
NCAV (Graham)
$17.09
$22.90
$34.18
51
Growth DCF
Growth DCF
$66.79
$117.92
$213.93
72
Rev-Margin DCF
$45.90
$78.85
$128.52
68
Economic Profit
Residual Income
$22.59
$20.54
$19.48
71
ROIC Compounder
$27.78
$31.01
$33.79
70
Growth Earnings
Growth-Adj P/E
$2.93
$4.18
$5.44
67
Notify me when 0HNC reaches fair value
Put 0HNC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
67/100
Of which business quality 68 · Market factors (momentum, volatility) 53
Profitability
27
Margins and returns on capital today
Quality Growth
35
Are margins and returns improving?
Cashflow
92
Earnings quality: real cash, not paper profit
Fin. Strength
89
Balance sheet, leverage, solvency risk
Investment
72
Disciplined investing over empire-building
Low Volatility
76
Calm price path (market factor)
Momentum
45
Price trend over the last 3–12 months (market factor)
52W Momentum
40
Distance to the 52-week high (market factor)
Net Issuance
89
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+13.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Start year 2020 (pandemic). Over 10 years: +14.0% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−50.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−50.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−6% → 17%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −2.2% a year for the price and +11.0% for the forecasts.
Forecast 2026 (sales)+20.2%
Forecast 2027 (sales)+14.3%
Projected 2028 (sales)+12.8%
Projected 2029 (sales)+11.2%
Projected 2030 (sales)+9.7%
Watch 0HNC, get fair value alerts →
Compare BioMarin Pharmaceutical Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Explore undervalued stocks
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is BioMarin Pharmaceutical Inc (0HNC) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $64.66 versus a price of $57.76, about +12% upside (undervalued).
What is the fair value of 0HNC?
Our model-based fair value for BioMarin Pharmaceutical Inc is $64.66 (as of Sep 24, 2026), built from audited fundamentals. The current price: $57.76.
What is the quality score of 0HNC?
BioMarin Pharmaceutical Inc has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioMarin Pharmaceutical Inc (0HNC)?
Our model-based price target is the fair value of $64.66 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $57.54, optimistic scenario $74.98. It is a calculation from audited fundamentals, not an analyst target.
What is the BioMarin Pharmaceutical Inc stock forecast for 2026?
Our models put fair value at $64.66, about +12% upside versus a price of $57.76 (undervalued). Cautious scenario $57.54, optimistic scenario $74.98. The calculation is refreshed regularly with new filings.
What is the revenue of BioMarin Pharmaceutical Inc (0HNC)?
BioMarin Pharmaceutical Inc reported trailing-twelve-month revenue of about $3.2B (latest available figure, as of Sep 24, 2026).
What growth is priced into BioMarin Pharmaceutical Inc (0HNC)?
For today's price to be fair in a discounted-cash-flow model, BioMarin Pharmaceutical Inc would have to grow free cash flow by +0.1 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0HNC use?
Our models discount BioMarin Pharmaceutical Inc at 9.0 %: a base by market capitalisation (unknown), damped by beta 0.24, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BioMarin Pharmaceutical Inc that is +0.1 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has BioMarin Pharmaceutical Inc (0HNC) delivered so far?
Over the past 5 years revenue at BioMarin Pharmaceutical Inc grew +11.8 % a year. The price currently implies +0.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of BioMarin Pharmaceutical Inc (0HNC)?
The free-cash-flow yield on the price is 6.55 %: that much free cash flow BioMarin Pharmaceutical Inc produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BioMarin Pharmaceutical Inc (0HNC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioMarin Pharmaceutical Inc it is $64.66 per share (as of Sep 24, 2026), against a price of $57.76. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is BioMarin Pharmaceutical Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0HNC trades below its calculated fair value: price $57.76, fair value $64.66, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0HNC?
No. The price is what the market pays today ($57.76); the fair value is what the company's own numbers justify ($64.66). For BioMarin Pharmaceutical Inc the two are $6.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioMarin Pharmaceutical Inc worth?
The market values BioMarin Pharmaceutical Inc at about $11.1B (market capitalisation, as of Sep 24, 2026). Per share that is $57.76; our models calculate a fair value of $64.66 per share.
What do the bullish and bearish scenarios say about 0HNC?
Our models span a range for BioMarin Pharmaceutical Inc: cautious scenario $57.54, base $64.66, optimistic $74.98 per share (as of Sep 24, 2026, price $57.76). The range comes from different growth and margin assumptions, not from analyst opinions.
Is BioMarin Pharmaceutical Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $57.76, calculated fair value $64.66 (+12%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0HNC calculated?
We run BioMarin Pharmaceutical Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $64.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. BioMarin Pharmaceutical Inc currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioMarin Pharmaceutical Inc (0HNC)?
The closing price on Oct 2, 2026 was $57.76. Our model-based fair value is $64.66, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioMarin Pharmaceutical Inc right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of BioMarin Pharmaceutical Inc
How large is the market capitalisation of BioMarin Pharmaceutical Inc (0HNC)?
The market capitalisation of BioMarin Pharmaceutical Inc is $11.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of BioMarin Pharmaceutical Inc (0HNC)?
The price-to-earnings ratio of BioMarin Pharmaceutical Inc is 2.7 (as of Jul 24, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of BioMarin Pharmaceutical Inc (0HNC)?
The price-to-sales ratio of BioMarin Pharmaceutical Inc is 0.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioMarin Pharmaceutical Inc (0HNC)?
Earnings per share at BioMarin Pharmaceutical Inc are $0.2150 (price ÷ EPS = P/E 2.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BioMarin Pharmaceutical Inc (0HNC)?
The net margin of BioMarin Pharmaceutical Inc is 0.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioMarin Pharmaceutical Inc (0HNC)?
The return on equity (ROE) of BioMarin Pharmaceutical Inc is 4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioMarin Pharmaceutical Inc (0HNC)?
On an EBIT basis the return on assets of BioMarin Pharmaceutical Inc is 3.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioMarin Pharmaceutical Inc (0HNC)?
The operating margin of BioMarin Pharmaceutical Inc is 18.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioMarin Pharmaceutical Inc (0HNC)?
Revenue at BioMarin Pharmaceutical Inc is growing +2.8% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioMarin Pharmaceutical Inc (0HNC)?
Earnings per share at BioMarin Pharmaceutical Inc are growing −43.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does BioMarin Pharmaceutical Inc (0HNC) hold?
BioMarin Pharmaceutical Inc holds more cash than debt, $715M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.